Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR006 PET for NFT detection in elderly subjects
NCT07115238Phase 3Recruiting
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of florquinitau in Alzheimer's disease (AD), sponsored by Sinotau Pharmaceutical Group. Started Nov 2024; status: recruiting.
02
Drugs
florquinitau
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07115238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115238.